research Chemotherapy-Induced Alopecia by Docetaxel: Prevalence, Treatment, and Prevention
Docetaxel often causes hair loss, with limited effective treatments and no cure for permanent hair loss.
Search
for
Sort by
Research
90-120 / 1000+ results 
research A Cornerstone of Hematological Science
The document concludes that accurately identifying leukemia types is crucial, and the risks of cancer from finasteride need careful evaluation against its benefits.
research Male Alopecia, Finasteride, and Cancer Risk
Finasteride for hair loss may increase the risk of certain cancers and has side effects; better regulation and education on its use are needed.
research How Not to Detect Prostate Cancer
Using a single PSA level to decide on a prostate biopsy is not effective; a more personalized approach considering various factors is recommended.
research Reduced Cardiotoxicity and Comparable Efficacy in a Phase III Trial of Pegylated Liposomal Doxorubicin HCl (CAELYX/Doxil) Versus Conventional Doxorubicin for First-Line Treatment of Metastatic Breast Cancer
Pegylated liposomal doxorubicin is as effective as conventional doxorubicin but causes fewer heart problems and side effects.
research First-In-Man Clinical Trial of the Oral Pan-AKT Inhibitor MK-2206 in Patients With Advanced Solid Tumors
MK-2206 was safe and effectively blocked AKT signaling in cancer patients, warranting more trials.
research Docetaxel
Docetaxel is effective against various cancers but mainly causes neutropenia.
research Postoperative Chemotherapy and Tamoxifen Compared with Tamoxifen Alone in the Treatment of Positive-Node Breast Cancer Patients Aged 50 Years and Older with Tumors Responsive to Tamoxifen: Results from the National Surgical Adjuvant Breast and Bowel Project B-16
Adding chemotherapy to tamoxifen improves survival for older breast cancer patients with positive nodes.
research Pathobiology of Chemotherapy-Induced Hair Loss
Chemotherapy causes hair loss by damaging hair follicles and stem cells, with more research needed for prevention and treatment.
research Cost-Effectiveness of Palliative Chemotherapy in Advanced Gastrointestinal Cancer
Palliative chemotherapy is cost-effective for advanced gastric and colorectal cancer but not clearly for pancreatic-biliary cancer.
research Permanent Alopecia After Cranial Irradiation: Dose–Response Relationship
Higher doses of cranial irradiation are linked to permanent hair loss.
research Prevention And Management Of Dermatological Toxicities Related To Anticancer Agents: ESMO Clinical Practice Guidelines
Early intervention and tailored management can reduce skin side effects from cancer treatments.
research Trichomegaly of the Eyelashes Following Treatment with Cetuximab
Cetuximab can cause excessive eyelash growth.
research Docetaxel, Cisplatin and 5-Fluorouracil in Patients with Locally Advanced Unresectable Head and Neck Cancer: A Phase I-II Feasibility Study
The treatment combining docetaxel, cisplatin, and 5-FU is feasible and effective for advanced head and neck cancer.
research Permanent Scalp Alopecia Related to Breast Cancer Chemotherapy by Sequential Fluorouracil/Epirubicin/Cyclophosphamide (FEC) and Docetaxel: A Prospective Study of 20 Patients
Some breast cancer chemotherapy can cause permanent hair loss.
research Fulvestrant: A New Treatment Option for Advanced Breast Cancer - Tolerability Versus Existing Agents
Fulvestrant is a well-tolerated new treatment for advanced breast cancer that may delay chemotherapy.
research Scalp Reconstruction Techniques After Oncologic Resection
Different scalp reconstruction methods work well, but the best one depends on the patient's unique needs.
research Weekly Docetaxel in Minimally Pretreated Cancer Patients: A Dose-Escalation Study Focused on Feasibility and Cumulative Toxicity of Long-Term Administration
Giving docetaxel weekly at 40 mg/m² is manageable and has low toxicity for cancer patients.
research Minoxidil as a Prophylaxis of Doxorubicin-Induced Alopecia
Minoxidil not effective in preventing chemotherapy-induced hair loss.
research Alopecia in Patients Treated with Molecularly Targeted Anticancer Therapies
Targeted cancer therapies have a significant but lower risk of causing hair loss compared to chemotherapy.
research Are Sex Discordant Outcomes in COVID-19 Related to Sex Hormones?
Sex hormones may affect COVID-19 severity, with men often faring worse, and targeting related pathways could offer treatment options.
research Advances in the Management of Cutaneous Toxicities of Targeted Therapies
Targeted cancer therapies often cause skin problems that need careful management to improve patient quality of life and treatment success.
research Male Pattern Baldness and the Risk of Prostate Cancer
Men who experienced baldness at age 20 may have double the risk of getting prostate cancer.
research Redefining Hormone Resistance in Prostate Cancer
The conclusion suggests that prostate cancer should be classified by castration status and that new therapies targeting androgen receptor signaling show promise.
research Acquired Hypertrichosis Lanuginosa: Case Report and Review of the Literature
A woman with breast cancer developed a rare condition causing excessive fine hair growth on her face and body.
research Fatal Toxic Epidermal Necrolysis Associated With Cetuximab in a Patient With Colon Cancer
A cancer patient died from a severe skin reaction after taking the drug cetuximab.
research Photobiomodulation Therapy in Management of Cancer Therapy-Induced Side Effects: WALT Position Paper 2022
Photobiomodulation therapy helps manage cancer treatment side effects but needs more research for optimization.
research Modeling of Chronic Radiation-Induced Cystitis in Mice
Researchers developed a mouse model that successfully mimics the bladder damage seen in humans after radiation therapy.
research Docetaxel and Oxaliplatin in the Second-Line Treatment of Platinum-Sensitive Recurrent Ovarian Cancer: A Phase II Study
Docetaxel and oxaliplatin are effective and have manageable side effects for recurrent platinum-sensitive ovarian cancer.
research Relationship Between Male Pattern Baldness and the Risk of Aggressive Prostate Cancer: An Analysis of the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial
Men with baldness at the front and top of their head at age 45 may have a higher risk of aggressive prostate cancer.